Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?

Neurol Sci. 2018 May;39(5):965-966. doi: 10.1007/s10072-017-3228-7. Epub 2018 Jan 4.

Authors

Chiara Rosa Mancinelli¹, C Scarpazza², G Santuccio³, N De Rossi², R Capra²

Affiliations

¹ Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018, Montichiari, Brescia, Italy. mancinellichiara86@gmail.com.
² Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018, Montichiari, Brescia, Italy.
³ Multiple Sclerosis Centre, Sondrio Hospital, ASST Valtellina-Alto Lario, 23100, Sondrio, Italy.

PMID: 29302813
DOI: 10.1007/s10072-017-3228-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antigens, CD20 / metabolism
Disability Evaluation
Female
Humans
Immunologic Factors / adverse effects*
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / diagnostic imaging
Magnetic Resonance Imaging
Multiple Sclerosis / drug therapy
Natalizumab / adverse effects*

Substances

Antigens, CD20
Immunologic Factors
Natalizumab